ASCLF (Ascletis Pharma) Debt-to-Equity : 0.00 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma Debt-to-Equity?

Ascletis Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.86 Mil. Ascletis Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.19 Mil. Ascletis Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $270.05 Mil. Ascletis Pharma's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ascletis Pharma's Debt-to-Equity or its related term are showing as below:

ASCLF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Ascletis Pharma Debt-to-Equity Historical Data

The historical data trend for Ascletis Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Debt-to-Equity Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Ascletis Pharma's Debt-to-Equity

For the Biotechnology subindustry, Ascletis Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Ascletis Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ascletis Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.858	+	0.191)	/	270.051
	=	0.00

Ascletis Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.858	+	0.191)	/	270.051
	=	0.00

Ascletis Pharma (OTCPK:ASCLF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ascletis Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

01672:Hong Kong 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.